When menin inhibitors are combined with a chemotherapy backbone like induction or Aza/Ven for newly diagnosed AML, the risk of differentiation syndrome (DS) is significantly lower than when they are used as monotherapy in the relapsed setting.
Similar to FLT3 inhibitors like midostaurin, which failed in the relapsed setting but succeeded upfront, menin inhibitors are expected to show dramatically better efficacy when combined with standard induction or HMA/Venetoclax in newly diagnosed patients.
Unlike typical targeted therapies that block a mutated receptor, menin inhibitors work by disrupting a master transcription complex. This forces leukemic cells to mature (differentiate) into terminal forms like neutrophils, after which they naturally die off.
The differentiation syndrome (DS) from menin inhibitors is often more severe and rapid than seen with other AML drugs. It can escalate into a "crisis" with DIC and heart failure, requiring an immediate drug pause, steroids, and potentially cytoreduction.
The activity of menin inhibitors is not strictly limited to patients with KMT2A or NPM1 mutations. Emerging data shows responses in patients with rare NUC98 rearrangements and those with a specific HOXA9 transcriptome signature, suggesting a wider potential use.
While MEN1 mutations cause resistance, they don't explain all treatment failures, especially with agents like Ziftomenib. Other mechanisms, including activation of RTK pathways (RAS, FLT3) and epigenetic bypass, are key drivers of acquired resistance.
The PARADIGM trial, showing Aza/Venetoclax is superior to intensive chemo for younger, fit patients, is not a universal finding. It explicitly excluded patients with favorable-risk cytogenetics and FLT3 mutations, meaning it applies mainly to a higher-risk subset.
Because menin inhibitors work by inducing cell differentiation rather than immediate cell death, clinicians must not expect rapid blast clearance. Complete remission may take two or more cycles to achieve, a significant departure from cytotoxic therapy timelines.